[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645365":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":32,"collaborators":7,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":7,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Geneplus-Beijing Co. Ltd.","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Fei Ma, MD","CONTACT","+8615010127581","drmafei@126.com",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","RECRUITING","Beijing","100100","China","CN",{"type":23,"coordinates":24},"Point",[25,26],116.39723,39.9075,{"lat":26,"lon":25},[29,30],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":31,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100645365","timing-of-ctdna-testing-in-advanced-breast-cancer-100645365",false,"NCT07681323","Timing of ctDNA Testing in Advanced Breast Cancer","Timing of ctDNA Testing in Advanced Breast Cancer: Impact on Prognosis and Treatment Strategies - A Prospective Observational Study (TIMING)","TIMING","Inclusion Criteria:\n\n* Histologically confirmed advanced breast cancer\n* Age ≥18 years\n* Expected survival \\>3 months\n* Willing to undergo ctDNA testing and sign informed consent form\n\nExclusion Criteria:\n\n* The subject has not signed the informed consent form.\n* Pregnant or breastfeeding women.\n* Other situations deemed by the investigator as unsuitable for inclusion in the study.","ALL","18 Years",{"count":45,"type":46},400,"ESTIMATED","OBSERVATIONAL","This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced breast cancer.",[50],"Advanced Breast Cancer",[52,53,54],"ctDNA","multigene testing","treatment strategy","2026-07-20",{"date":57,"type":58},"2026-07-22","ACTUAL",{"date":60,"type":46},"2026-07-08",{"date":62,"type":46},"2029-06-30",{"name":5,"class":6},1]